Alpha-Defensin vs BPC-157
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Alpha-Defensin
Alpha-defensins are small cationic peptides that are key components of the innate immune system. They have broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses.
Full details →BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →Side-by-Side Comparison
| Aspect | Alpha-Defensin | BPC-157 |
|---|---|---|
| Dose Range | 100 mcg–500 mcg | 250 mcg–500 mcg |
| Frequency | 1x daily | 2x daily |
| Cycle Length | 2–4 weeks | 4–6 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Insert into microbial membranes to form pores, leading to cell death. Also have immunomodulatory effects including chemotaxis of immune cells and cytokine modulation. | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. |
| Typical Dosage | Research compound - dosing varies by application. Typically studied in laboratory and early clinical research settings rather than for general use. | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. |
| Administration | Various routes studied including topical, local injection, and systemic administration depending on application. | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. |
| Side Effects | Limited human use data. May cause local inflammation. Potential for immune activation effects. | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. |
| Best For |
What They Have in Common
Alpha-Defensin, BPC-157 are both commonly used for:
Key Differences
Unique to Alpha-Defensin:
Unique to BPC-157:
Which Has Stronger Evidence?
- Recovery & Healing: BPC-157 has stronger research support.
| Goal | Alpha-Defensin | BPC-157 |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
Alpha-Defensin
- AhR Activation Transcriptionally Induces Anti-Microbial Peptide Alpha-Defensin 1 Leading to Reversal of Gut Microbiota Dysbiosis and Colitis.
Gut microbes, 2025
- Alpha-defensin binding expands human adenovirus tropism.
PLoS pathogens, 2024
- Alpha-Defensin 1: An Emerging Periodontitis Biomarker.
Diagnostics (Basel, Switzerland), 2023
BPC-157
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Current reviews in musculoskeletal medicine, 2025
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Alternative therapies in health and medicine, 2024
Ready to Learn More?
Looking for trusted sources?